Haleon has added a line of products to its well-established Panadol portfolio in the UK under new sub-brand Panmigrol.
Haleon Launches Panadol Sub-Brand For UK Migraine Sufferers
Available in UK pharmacies and supermarkets, Panmigrol’s “triple-action formulation” provides more effective migraine relief than standard ibuprofen or sumatriptan tablets, manufacturer Haleon claims.
More from United Kingdom
• By
Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.
• By
Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”
• By
Advercheck managing director James Walmsley talks to HBW Insight about the challenges facing consumer health companies today as they move away from the prescription medicines sector and its pipeline of switchable ingredients towards self-care and prevention.
More from Innovation & IP
• By
Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.
• By
Advercheck managing director James Walmsley talks to HBW Insight about the challenges facing consumer health companies today as they move away from the prescription medicines sector and its pipeline of switchable ingredients towards self-care and prevention.
• By
Start-ups and individuals working on innovative consumer health concepts, in categories such as pain relief and dietary supplements, have the opportunity to access Haleon's resources and expertise to make their ideas a reality.